本文選題：Hib結(jié)合疫苗 + 免疫原性��； 參考：《重慶醫(yī)科大學(xué)》2010年碩士論文

【摘要】： 目的:以大鼠為模型,對(duì)市場(chǎng)上常見(jiàn)的三種Hib結(jié)合疫苗的免疫原性進(jìn)行研究,比較三種疫苗產(chǎn)生的抗體水平,了解幾種疫苗之間免疫原性是否具有差別,為兒童選擇接種Hib疫苗提供可靠的依據(jù),為將Hib疫苗納入計(jì)劃免疫提供一定的基礎(chǔ)。 方法:選擇SPF級(jí)5天齡的SD大鼠共128只,清潔級(jí)動(dòng)物間母乳喂養(yǎng),21天齡左右離乳。將5d齡乳鼠隨機(jī)分組,共四組。包括實(shí)驗(yàn)組3組(賀新立適組、安爾寶組、云南玉溪組),35只/組,對(duì)照組(生理鹽水組)1組,23只/組。在5d,19d,26d齡時(shí)給予相應(yīng)疫苗(生理鹽水)20μl皮下免疫注射。獲得初次免疫前及末次免疫后1周,2周,4周的血清。使用ELISA法測(cè)定各組血清中Hib IgG抗體。比較每組注射疫苗前后的抗體水平,比較各組間的抗體水平。 結(jié)果:實(shí)驗(yàn)組疫苗注射前后抗體濃度比較,差異性顯著,末次免疫后1周時(shí)抗體濃度均較免疫前明顯增高(p0.01),第2周時(shí)抗體濃度繼續(xù)升高(p0.01),第4周時(shí)有明顯下降趨勢(shì)(p0.01);對(duì)照組不同時(shí)間抗體濃度無(wú)明顯差異(p0.01)。各組間抗體濃度比較,其結(jié)果如下:免疫前組間抗體水平不存在顯著性差異(p0.01)。末次免疫后1周,各實(shí)驗(yàn)組與對(duì)照組間均存在顯著性差異(p0.01),賀新立適組抗體濃度最高,與安爾寶組無(wú)明顯差異(p0.01),與云南組間存在顯著性差異(p0.01),安爾寶組與云南組差異不顯著(p0.01);末次免疫后2周及4周,賀新立適組抗體濃度較高,與安爾寶組、云南組之間均存在顯著性差異(p0.01),安爾寶組與云南組差異不顯著(p0.01)。 結(jié)論:三種Hib結(jié)合疫苗均具有良好的免疫原性;三種Hib疫苗產(chǎn)生的抗體濃度變化趨勢(shì)大致相同,在不同抗體水平基礎(chǔ)上,均在免疫后第1周有抗體產(chǎn)生,第2周時(shí)繼續(xù)增高,第4周有明顯的下降。賀新立適產(chǎn)生的抗體始終處于較高水平,安爾寶與國(guó)產(chǎn)Hib疫苗無(wú)顯著差異。免疫接種時(shí)推薦優(yōu)先使用賀新立適,可作為兒童Hib預(yù)防接種的良好選擇。
[Abstract]:Objective: to study the immunogenicity of three Hib conjugated vaccines in the market in rats, compare the antibody levels of the three vaccines and find out whether there are differences in the immunogenicity of the three vaccines. Methods: 128 SD rats of SPF grade 5 days old were selected and breast-fed between clean grade animals about 21 days old. Five day old neonatal rats were randomly divided into four groups. There were 35 rats in the experimental group (Hexinlishi group, Anerbao group, Yuxi group, Yunnan province) and 23 rats in the control group (normal saline group). The corresponding vaccine (20 渭 l saline) was injected subcutaneously at the age of 26 days. The serum was obtained before the first immunization and 1 week and 4 weeks after the last immunization. Hib IgG antibody in serum of each group was determined by Elisa. The antibody levels of each group before and after vaccination were compared. Results: the concentration of antibody in the experimental group was significantly different before and after the injection of vaccine. After the last immunization, the antibody concentration was significantly higher at 1 week than that before immunization, and continued to increase at the second week, and decreased significantly at the 4th week, but there was no significant difference between the control group and the control group at different time points (P 0.01). The results were as follows: there was no significant difference in antibody level between groups before immunization (p 0.01). One week after the last immunization, there was a significant difference between the experimental group and the control group (p0.01), and the highest antibody concentration was found in the Hexinlsuo group. There was no significant difference between Anerbao group and Yunnan group, but there was no significant difference between Anerbao group and Yunnan group (P 0.01), but there was no significant difference between Anerbao group and Yunnan group (P 0.01), and the concentration of antibody in Hexinlite group was higher than that in Anerbao group at 2 and 4 weeks after the last immunization. There was significant difference between Yunnan group and Yunnan group, but there was no significant difference between Anerbao group and Yunnan group. Conclusion: all the three Hib conjugated vaccines have good immunogenicity, and the change trend of antibody concentration of the three Hib vaccines is about the same. On the basis of different antibody levels, antibodies were produced at the first week after immunization, continued to increase at the second week, and decreased significantly at the fourth week. The antibody produced by he Xinlishi was always at a high level, and there was no significant difference between the vaccine of Albo and Hib vaccine made in China. Hexinlite is recommended as a good choice for Hib vaccination in children.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2010
【分類號(hào)】：R392

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳洪;嬰兒對(duì)7價(jià)肺炎球菌結(jié)合疫苗的初次和加強(qiáng)唾液抗體應(yīng)答[J];國(guó)外醫(yī)學(xué).預(yù)防.診斷.治療用生物制品分冊(cè);2001年03期

2 盧儉奮;含滅活的HAV抗原和重組HBsAg的肝炎結(jié)合疫苗[J];國(guó)際生物制品學(xué)雜志;1990年05期

3 談寧芝,栗克喜,劉玉清,馮曉虎,蔡勤,余文三;14型肺炎球菌莢膜多糖-破傷風(fēng)類毒素結(jié)合疫苗研究[J];中華微生物學(xué)和免疫學(xué)雜志;2002年06期

4 林端端;七價(jià)肺炎球菌結(jié)合疫苗的效果評(píng)價(jià)[J];國(guó)外醫(yī)學(xué).預(yù)防.診斷.治療用生物制品分冊(cè);2003年01期

5 田博;無(wú)脾患者對(duì)肺炎球菌結(jié)合疫苗的抗體應(yīng)答[J];國(guó)外醫(yī)學(xué).預(yù)防.診斷.治療用生物制品分冊(cè);2002年06期

6 張世勇;健康兒童接種7價(jià)肺炎鏈球菌結(jié)合疫苗可減少該菌所致的疾病[J];國(guó)外醫(yī)學(xué).流行病學(xué).傳染病學(xué)分冊(cè);2002年04期

7 王燕,吳朝今,杜送田,蔣奕,雍元,李岷松,趙志強(qiáng),蔣仁生,杜琳,謝貴林;大腸桿菌O157∶H7多糖-重組銅綠假單胞菌外毒素A結(jié)合疫苗的研制[J];中華微生物學(xué)和免疫學(xué)雜志;2004年11期

8 何平;Ⅱ型B群鏈球菌莢膜多糖結(jié)合疫苗在健康婦女中的安全性和免疫原性[J];國(guó)外醫(yī)學(xué).預(yù)防.診斷.治療用生物制品分冊(cè);2001年03期

9 王軼文;單價(jià)和多價(jià)KLH結(jié)合疫苗免疫后抗體水平比較[J];國(guó)外醫(yī)學(xué).預(yù)防.診斷.治療用生物制品分冊(cè);2003年02期

10 雍元,杜琳,邱曉玲,王燕,何向東,謝貴林;不同蛋白載體的痢疾多糖結(jié)合疫苗小鼠免疫原性對(duì)比試驗(yàn)[J];微生物學(xué)免疫學(xué)進(jìn)展;2003年04期

相關(guān)會(huì)議論文 前10條

1 李軍強(qiáng);孫倩;李小強(qiáng);;比較Hib在不同培養(yǎng)基中的生長(zhǎng)狀況和產(chǎn)糖能力的研究[A];2011年中國(guó)藥學(xué)大會(huì)暨第11屆中國(guó)藥師周論文集[C];2011年

2 農(nóng)藝;李艷萍;李亞楠;陳福生;李春松;黃月葵;葉強(qiáng);;b型流感嗜血桿菌結(jié)合疫苗免疫原性的比較研究[A];第五次全國(guó)免疫診斷暨疫苗學(xué)術(shù)研討會(huì)論文匯編[C];2011年

3 韓星;張卉;高強(qiáng);;B型流感嗜血桿菌(HIB)與HIB疫苗[A];第五次全國(guó)免疫診斷暨疫苗學(xué)術(shù)研討會(huì)論文匯編[C];2011年

4 馬慶華;付元欣;魏然;高雪軍;朱莉萍;;多糖蛋白結(jié)合疫苗中殘余碳二亞胺(EDAC)的檢測(cè)方法的建立[A];第五次全國(guó)免疫診斷暨疫苗學(xué)術(shù)研討會(huì)論文匯編[C];2011年

5 李紅;李茂光;唐靜;梁麗;李亞南;何莉;葉強(qiáng);;定量測(cè)定血清中Hib總抗體ELISA方法的建立[A];2010年中國(guó)藥學(xué)大會(huì)暨第十屆中國(guó)藥師周論文集[C];2010年

6 楊e，

本文編號(hào)：1992544